Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Epic Research is a leading financial services provider with presence in Indian and other global capital markets. Provides Stock Tips, Forex Tips, Commodity Tips, MCX Tips, Equity Tips, Intraday Tips, NSE Tips, BSE Tips, COMEX Tips, PCG Pack and NCDEX Tips. We provide services in equity, commodity and Forex market.

  • Be the first to comment

  • Be the first to like this


  1. 1. HEADLINES  Indian Market Indian equity markets down by 0.30%. Nifty down by 21.35 pts and settle at 5738.75 Sensex down by 56.15 pts at 18846.26. Bank Nifty down by 51.95 pts at 11613.55  Global Market DAILY EQUITY European markets were up with FTSE NEWSLETTER up by 18.03 pts at 5809.66,CAC up by 13.45 pts at 3423.04 and DAX up by 9TH NOVEMBER 2012 37.58 pts at 7270.41 Dow future up by 16.00pts at 12879.00  HEADLINES• SAIL Q2 profit rises 12% to Rs 543 cr, misses estimates• Ranbaxy turns profitable on forex gain, Q3 net at Rs 754cr• NTPC generation capacity increases to 39,674 MW• Sun Pharma Q2 net falls 46% to Rs 320 cr on one-time loss WWW.EPICRESEARCH.CO 09752199966
  2. 2.  MARKET ANALYSIS:  Key benchmark indices cut losses in late trade with the 50-unit S&P CNX Nifty hitting an intraday high. European stocks advanced after the Greek parliament late on Wednesday, 7 November 2012, passed a fresh round of austerity measures necessary to ensure the release of the latest round of aid to the country from its international creditors.  BSE Sensex was down 66.98 points or 0.35% to 18,835.43.  The S&P CNX Nifty was down 23.70 points or 0.41% to 5,736.40.  From the 30-share Sensex pack, 21 stocks declined while the rest of them rose.  Sun Pharmaceutical Industries fell 0.89% after consolidated net profit fell 46.53% to Rs 319.64 crore on 40.36% increase in total income to Rs 2833.13 crore in Q2 September 2012 over Q2 September 2011. Ranbaxy Laboratories lost 0.25% after the company reported consolidated net profit of Rs 754.20 crore in Q3 September 2012, compared with net loss of Rs 464.60 crore in Q3 September 2011. The company announced the results during trading hours today, 8 November 2012. STOCKS TO WATCH  FII’s and DII’s  HINDALCOCATEGORY DATE BUY SELL NET  VIP FII 8-Nov-12 2053.35 1792.14 261.21  ARVIND  JP ASSOCIATE DII 8-Nov-12 901.63 817.05 84.58 SCRIPS IN BAN PERIOD  NIFTY DAILY PIVOTS  HDILPIVOT R4 R3 R2 R1 PP S1 S2 S3 S4NIFTY 5878 5827 5776 5757 5725 5706 5674 5623 5572  SUZLON  MC-DOWELL WWW.EPICRESEARCH.CO 09752199966
  3. 3. .  -GAINERS AND LOOSERS EXPERT OPINION NIFTY DAILY NIFTY GAINERS  Nifty looks SidewaysSCRIPS RATE VOL. PR. NET %  Strategy: Buy on dips (000) CLOSE CHAN CHANG GE E  Support:5690 Tata 283.95 24412.62 269.35 14.60 5.42  Resistance: 5790Motors Bharti BANK NIFTY 277.05 6950.76 271.10 5.95 2.19 Airtel  Bank Nifty looks Sideways Wipro 375.40 2353.48 367.85 7.55 2.05  Strategy: Buy on dips Asian Paints 4178.10 87.10 4120.45 57.65 1.40  Support:11550 DLF 214.00 5237.32 211.50 2.50 1.18  Resistance:11690  PREVIOUS PERFORMANCE DAILY NIFTY LOOSERS TYPE SCRIP B/S RESULTSCRIPS RATE VOL. PR. NET % (000) CLOSE CHAN CHA NOT CASH APTECH B EXECUTED GE NGE APOLLO TGT CASH S GAIL TYRE ACHIEVED 358.60 1070.95 366.10 -7.50 -2.05 India BHARTI FUTURE S ABOVE COST Larsen & AIRTEL 1635.35 1374.40 1669.45 -34.10 -2.04 Toubro NOT Tata FUTURE IRB INFRA B 101.75 2683.43 103.80 -2.05 -1.97 EXECUTED Power Reliance 476.35 1966.13 485.05 -8.70 -1.79 Infra UPCOMING RESULTS IDFC 163.60 4719.71 166.40 -2.80 -1.68  SBI  HPCL  IOC  COAL INDIA  HDIL 09752199966
  4. 4. MARKET CALLS CASH ST ND SCRIPS ACTION LEVEL 1 TARGET 2 TARGET STOP LOSS APOLLO TYRE SELL 82.30 81.60 80.60 83.05 HDIL BUY 106.05 106.95 108.00 105.15 FUTURE ST ND SCRIPS ACTION LEVEL 1 TARGET 2 TARGET STOP LOSS. VOLTAS BUY 114.80 115.80 117.30 113.80 JP ASSOCIATE SELL 92.55 92.05 91.30 92.95 Disclaimer The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE. The share price projections shown are not necessarily indicative of future price performance. The information herein, togethe r with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer. All Rights Reserved. Investment in equity & bullion market has its own risks. We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoev er for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.